Search Results - Jennifer R Diamond

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. by Youngchul Kim, Saketh R Guntupalli, Sun J Lee, Kian Behbakht, Dan Theodorescu, Jae K Lee, Jennifer R Diamond

    Published in PLoS ONE (2014-01-01)
    Get full text
    Article


  2. 2

    Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer by Anna R. Schreiber, Stephen G. Smoots, Marilyn M. Jackson, Stacey M. Bagby, Evan D. Dus, Adrian T. A. Dominguez, Cameron A. Binns, Todd M. Pitts, Jennifer R. Diamond

    Published in Frontiers in Oncology (2025-04-01)
    Get full text
    Article


  3. 3

    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis by Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond, Todd M. Pitts

    Published in Breast Cancer Research (2024-03-01)
    Get full text
    Article


  4. 4

    Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors by Jarushka Naidoo, Maria L Ascierto, Matthew D Hellmann, Ding Wang, Susana Banerjee, Mayukh Das, Panagiotis Kourtesis, Jennifer R Diamond, Teresa Alonso-Gordoa, Sandip P Patel, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Benedito A Carneiro

    Published in Journal for ImmunoTherapy of Cancer (2024-02-01)
    Get full text
    Article


  5. 5

    Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center by Ahmed Alsafar, Sama L. Kareem, Bradley R. Corr, Christopher H. Lieu, Breelyn Wilky, S. Lindsey Davis, D. Ross Camidge, Antonio Jimeno, Wells A. Messersmith, Andrew Nicklawsky, Daniel Pacheco, Evelinn A. Borrayo, Jessica D. McDermott, Jennifer R. Diamond

    Published in Frontiers in Oncology (2025-07-01)
    Get full text
    Article


  6. 6

    ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer by S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts

    Published in BMC Cancer (2022-10-01)
    Get full text
    Article


  7. 7

    Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis by Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés

    Published in npj Breast Cancer (2022-06-01)
    Get full text
    Article


  8. 8

    Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer by Anthony D. Elias, Alyse W. Staley, Monica Fornier, Gregory A. Vidal, Vida Alami, Sharon Sams, Nicole S. Spoelstra, Andrew Goodspeed, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathryn L. Zolman, Tessa McSpadden, Kimberly R. Jordan, Jill E. Slansky, Virginia F. Borges, Dexiang Gao, Jennifer K. Richer

    Published in npj Breast Cancer (2024-10-01)
    Get full text
    Article


  9. 9

    Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes by Juan A. Marín-Jiménez, Anna Capasso, Matthew S. Lewis, Stacey M. Bagby, Sarah J. Hartman, Jeremy Shulman, Natalie M. Navarro, Hui Yu, Hui Yu, Chris J. Rivard, Chris J. Rivard, Xiaoguang Wang, Jessica C. Barkow, Degui Geng, Adwitiya Kar, Ashley Yingst, Dejene M. Tufa, James T. Dolan, Patrick J. Blatchford, Brian M. Freed, Brian M. Freed, Raul M. Torres, Raul M. Torres, Eduardo Davila, Eduardo Davila, Jill E. Slansky, Jill E. Slansky, Roberta Pelanda, Roberta Pelanda, S. Gail Eckhardt, Wells A. Messersmith, Wells A. Messersmith, Jennifer R. Diamond, Jennifer R. Diamond, Christopher H. Lieu, Michael R. Verneris, Jing H. Wang, Jing H. Wang, Katja Kiseljak-Vassiliades, Katja Kiseljak-Vassiliades, Todd M. Pitts, Todd M. Pitts, Julie Lang

    Published in Frontiers in Immunology (2021-03-01)
    Get full text
    Article


  10. 10

    Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer by Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer

    Published in npj Breast Cancer (2023-05-01)
    Get full text
    Article


Search Tools: